What's new? Log in Free sign up

Home
Sectors & IndustriesSectors
Earnings
IPOs
Transcripts
Insider
Institutional
Splits

BNTX Dashboard
Financials
Filings
Holdings
Transcripts
ETFs
Insider
Institutional
Shorts
6-K Filing

BioNTech SE (BNTX) 6-KBioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Filed: 20 Mar 24, 7:11am

Free signup for more

Track your favorite companies
Receive email alerts for new filings
Personalized dashboard of news and more
Access all data and search results

Search this filing

All

Tables only

Footnotes only

Pre-defined:

Table of contents

Filing tables

Export all tables to Excel

Filing exhibits

6-K Current report (foreign)
99.1 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

BNTX similar filings

8 Apr 24 Invitation to the Annual General Meeting 2024
8 Apr 24 Current report (foreign)
20 Mar 24 BioNTech Announces Fourth Quarter and Full Year 2023
20 Mar 24 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
11 Mar 24 BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
7 Mar 24 BioNTech Announces Planned Retirement of Sean Marett
8 Feb 24 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Filing view

Default size S M L
Default font Times Arial

External links

View on EDGAR (sec.gov)

Share this filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MARCH 2024

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On March 20, 2024, BioNTech SE announced that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. The press release is attached hereto as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


			BioNTech SE


			By:			/s/ Dr. Sierk Poetting
						Name: Dr. Sierk Poetting
						Title: Chief Operating Officer

Date: March 20, 2024

EXHIBIT INDEX



Exhibit			Description of Exhibit

99.1			BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Resources

Knowledgebase
Log In
Register

Company

About
Contact
Solutions

Products

Deal Roadshow
DealVDR
Evercall
Finsight.com

CapEdge

Earnings Calendar
Earnings Transcripts
EDGAR Filing Screener
IPO Calendar

Compliance
Privacy
Security
Terms

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.